[go: up one dir, main page]

UY27694A1 - Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo. - Google Patents

Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo.

Info

Publication number
UY27694A1
UY27694A1 UY27694A UY27694A UY27694A1 UY 27694 A1 UY27694 A1 UY 27694A1 UY 27694 A UY27694 A UY 27694A UY 27694 A UY27694 A UY 27694A UY 27694 A1 UY27694 A1 UY 27694A1
Authority
UY
Uruguay
Prior art keywords
methyl
amino
ethyl ester
acid
salts
Prior art date
Application number
UY27694A
Other languages
English (en)
Spanish (es)
Inventor
Dr Ulrich Brauns
Dr Norbert Hauel
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27694A1 publication Critical patent/UY27694A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UY27694A 2002-03-07 2003-03-06 Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo. UY27694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze

Publications (1)

Publication Number Publication Date
UY27694A1 true UY27694A1 (es) 2003-10-31

Family

ID=27771070

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27694A UY27694A1 (es) 2002-03-07 2003-03-06 Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo.

Country Status (4)

Country Link
CN (1) CN101632668A (ru)
DE (1) DE10209985A1 (ru)
UA (2) UA81760C2 (ru)
UY (1) UY27694A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6215239B2 (ja) 2012-02-21 2017-10-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ダビガトランエテキシラートの経口医薬組成物
CN102793699B (zh) * 2012-08-06 2014-06-04 严轶东 一种含有达比加群酯的药用组合物
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
CN105640909B (zh) 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法

Also Published As

Publication number Publication date
DE10209985A1 (de) 2003-09-25
CN101632668A (zh) 2010-01-27
UA81760C2 (ru) 2008-02-11
UA95601C2 (ru) 2011-08-25

Similar Documents

Publication Publication Date Title
UY28468A1 (es) Tableta que contiene el éster etílico de ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico o sus sales.
ECSP045331A (es) Forma de presentación para administración por vía oral, para éster etílico de ácido 3?[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-?bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico y sus sales
UY29493A1 (es) Sales fisiológicamente compatibles de éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico
UY28493A1 (es) Metanosulfonato del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico y su utilización como medicamento.
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
CY2013015I2 (el) Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος
EA200901186A1 (ru) S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ
HN2005000016A (es) Procedimiento de preparacion
CY1114925T1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
HRP20110094T8 (en) Solid preparation comprising alogliptin and pioglitazone
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
PE20090641A1 (es) Amidas heterociclicas
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
GT200800280A (es) Polimorfo de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
CL2024000758A1 (es) Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
PE20090875A1 (es) Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos
UY27694A1 (es) Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo.
PE20140018A1 (es) Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica
CY1107300T1 (el) Ακυλικα παραγωγα της 5-(2-(4-(1,2-βενζισοθειαζολ-3-υλο)-1-πιπεραζινυλ)αιθυλο)-6-χλωρο-1,3-διυδρο-2h-ινδολ-2-ονης με νευροληπτικη δραστικοτητα
DE602006015291D1 (de) Hiv-inhibierende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidine

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161118